Kaletra

Lopinavir, the active ingredient in Kaletra, is a protease inhibitor presented as a 200 mg/50 mg tablet for oral use. It is used in combination therapy to treat HIV‑1 infection and AIDS in adults and children, helping to reduce viral load and improve immune function.

GNH USA supplies Kaletra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict GMP conditions.

Kaletra (lopinavir/ritonavir) is employed in antiretroviral therapy targeting the HIV replication cycle.

HIV‑1 infection: reduces viral load and slows disease progression. AIDS: improves immune function and decreases opportunistic infections. Treatment‑experienced HIV infection: provides an effective option when resistance to other protease inhibitors has developed. Pediatric HIV‑1 infection: used under specialist supervision to achieve viral suppression in children.

Lopinavir/ritonavir may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools that may lead to dehydration and electrolyte imbalance. - Nausea: feeling of sickness often accompanied by loss of appetite. - Headache: mild to moderate head pain that can affect daily activities. - Elevated lipids: increase in cholesterol and triglyceride levels observed in blood tests.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or hepatitis requiring monitoring and possible discontinuation. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis demanding immediate medical attention. - QT prolongation: potential heart rhythm disturbance that may require ECG monitoring.

When prescribing Kaletra, clinicians should consider several safety measures.

Liver monitoring: perform baseline and periodic liver function tests to detect hepatotoxicity. Lipid assessment: regularly check cholesterol and triglyceride levels and manage dyslipidemia. Resistance evaluation: avoid use if documented resistance to lopinavir or other protease inhibitors. Adherence counseling: emphasize strict dosing schedule to prevent viral resistance and treatment failure. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Kaletra interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort): markedly reduce lopinavir levels. - Co‑administration with other protease inhibitors at high doses: may increase toxicity. - QT‑prolonging agents (e.g., amiodarone, sotalol): raise risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Certain statins (simvastatin, lovastatin): increased risk of myopathy; dose adjustment required. - Anti‑arrhythmics (diltiazem, verapamil): may raise lopinavir concentrations. - Oral contraceptives: efficacy may be reduced; consider alternative contraception. - Glucocorticoids (e.g., dexamethasone): altered metabolism may necessitate dose changes.